Skip To Main Content
Hellmann MD on Muck Rack

Hellmann MD

As seen in: Oxford University Press (OUP)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Hellmann MD’s profile

Articles by Hellmann MD

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results

|
By Lam WS, Hellmann MD, Gubens MA, Tan DSW
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (602) Issue with article?

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

|
By Hellmann MD, Vokes NI, Arniella MB, Freeman SS
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (412) Issue with article?

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

|
By Hellmann MD
| ncbi.nlm.nih.gov
Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per megabase).
Open in Who Shared Issue with article?

‘Genotype/immunotype’ correlations in resected NSCLC

|
By Paik PK, Hellmann MD
| Oxford University Press (OUP)
Immunotherapy, broadly classified as anti-cancer treatments that potentiate the immune system’s ability to recognize and destroy cancer cells, is now a standard of care for patients with non-small cell lung cancers (NSCLCs). Monoclonal antibodies directed against the T-cell inhibitory receptor PD-1 and its ligand PD-L1 are available from several companies and have supplanted, for many patients, chemotherapy as the superior treatment option within a given line of therapy.
Open in Who Shared Issue with article?
Show More